Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab Alone or in Combination in Japanese Participants With Non-Hodgkin Lymphoma
NCT04661007Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Dec 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Started Dec 2020; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04661007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661007.